0
Original Research: COPD |

Normal Bronchial Blood Flow in COPD Is Unaffected by Inhaled Corticosteroids and Correlates With Exhaled Nitric Oxide*

Paolo Paredi, MD, PhD; Simon Ward, BSc; Derek Cramer, MIScT, CE, Dip M; Peter J. Barnes, DM, DSc, FCCP; Sergei A. Kharitonov, MD, PhD
Author and Funding Information

*From the Section of Airway Disease (Drs. Paredi, Barnes, and Kharitonov), National Heart and Lung Institute, Imperial College, London, UK; and Lung Function Unit (Mr. Ward and Mr. Cramer), Royal Brompton Hospital, London, UK.

Correspondence to: Paolo Paredi, MD, PhD, National Heart and Lung Institute, Airway Disease Section, Dovehouse St, London, SW3 6LY, UK; e-mail: p.paredi@imperial.ac.uk



Chest. 2007;131(4):1075-1081. doi:10.1378/chest.06-2154
Text Size: A A A
Published online

Background: In COPD patients, there is reduced vascularity and inflammation of the bronchi, which may have opposite effects on bronchial blood flow (QAW). We studied the relationship of QAW with the fraction of exhaled nitric oxide (FENO), which is a potent vasodilator. We also investigated the vascular response to budesonide and a β2-agonist.

Methods: We measured QAW in 17 patients with COPD (mean [± SEM] age, 67 ± 3 years; 10 male patients; mean FEV1, 57 ± 3% predicted; mean FEV1/FVC ratio, 54 ± 4%), all of whom were ex-smokers, and in 16 age-matched nonsmoking volunteers (mean age, 64 ± 4 years) and compared this to FENO. QAW was measured using the acetylene dilution method.

Results: Mean QAW was similar in patients with COPD (34.29 ± 1.09 μL/mL/min) compared to healthy subjects (35.50 ± 1.74 μL/mL/min; p > 0.05) and was not affected by long-term treatment (35.89 ± 1.63 μL/mL/min) or short-term treatment (32.50 ± 1.24 μL/mL/min; p < 0.05) with inhaled budesonide. QAW positively correlated with the diffusion of carbon monoxide (ie, carbon monoxide transfer coefficient: r = 0.74; p < 0.05). FENO levels were mildly elevated in steroid-treated patients (10.89 ± 0.87 parts per billion [ppb]) and untreated patients (9.40 ± 0.86 ppb) compared to the control group (8.22 ± 0.57 ppb; p < 0.05) and were correlated with QAW (r = 0.6; p < 0.05). Ten minutes after the inhalation of 200 μg of albuterol, QAW was more elevated in healthy control subjects (59.33 ± 2.40 μL/mL/min) compared to COPD patients (38.00 ± 0.58 μL/mL/min; p < 0.05), indicating that COPD patients may have a reduced bronchial vascular reactivity.

Conclusions: QAW is normal in COPD patients and is not affected by therapy with inhaled corticosteroids or β2-agonists. In addition, QAW correlates with levels of FENO, which may have a regulatory role.

Figures in this Article

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543